MCID: HRP004
MIFTS: 61

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Herpes Zoster

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 76 25 54 55 3 44 15
Shingles 12 76 25 54 43 3 15 63
Zoster 25 3
Herpes Zoster Disease 73
Herpes Zona 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 35 053
MeSH 44 D006562
NCIt 50 C71079
SNOMED-CT 68 4740000
UMLS 73 C0019360

Summaries for Herpes Zoster

MedlinePlus : 43 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What are the complications of shingles? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to postherpetic neuralgia and viral infectious disease, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is DPYD (Dihydropyrimidine Dehydrogenase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Foscarnet and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells.

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Genetics Home Reference : 25 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.

CDC : 3 Almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However, the risk of shingles increases as you get older.

NINDS : 54 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 63 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body.People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox.Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications.Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 76 Shingles, also known as herpes zoster, is a viral disease characterized by a painful skin rash with... more...

Related Diseases for Herpes Zoster

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 591)
# Related Disease Score Top Affiliating Genes
1 postherpetic neuralgia 33.1 HLA-A HLA-B
2 viral infectious disease 30.5 IFNA2 IFNG IL10 IL2
3 uveitis 30.4 HLA-B IFNA2 IFNG IL10
4 anterior uveitis 30.4 HLA-A HLA-B
5 human immunodeficiency virus infectious disease 30.3 IFNG IL10 IL2
6 inflammatory bowel disease 30.3 HLA-B IFNG IL10 IL2 TRPV1
7 rubella 30.2 HLA-A HLA-B IL10
8 pityriasis rosea 30.2 HLA-A HLA-B
9 discoid lupus erythematosus 30.2 IFNA2 IL10
10 folliculitis 30.2 FCGR3A IFNG
11 ulcerative colitis 30.2 IFNG IL10 IL2
12 colitis 30.2 IFNG IL10 IL2
13 alopecia areata 29.9 HLA-A IFNG IL2
14 rheumatic disease 29.8 HLA-B IFNG IL10
15 mouth disease 29.8 IFNG IL10 TRPV1
16 panuveitis 29.8 HLA-A HLA-B IL10
17 vogt-koyanagi-harada disease 29.8 HLA-A HLA-B IL10
18 lepromatous leprosy 29.8 IFNG IL10 IL2
19 leishmaniasis 29.7 IFNG IL10 IL2
20 toxic shock syndrome 29.7 IFNG IL10 IL2
21 chronic graft versus host disease 29.7 IFNG IL10
22 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.7 IFNG IL10 IL2
23 tetanus 29.7 IFNG IL10 IL2
24 pulmonary tuberculosis 29.7 IFNG IL10 IL2
25 connective tissue disease 29.7 IFNG IL10 TRPV1
26 severe cutaneous adverse reaction 29.7 HCP5 HLA-A HLA-B
27 common variable immunodeficiency 29.7 IFNG IL10 IL2
28 autoimmune disease 29.7 COL17A1 FCGR3A HLA-B IFNG IL10 IL2
29 sarcoidosis 1 29.6 HLA-A IFNG IL2
30 hematopoietic stem cell transplantation 29.6 HLA-A HLA-B IFNG IL10 IL2
31 graft-versus-host disease 29.6 HLA-A HLA-B IFNG IL10 IL2
32 acquired immunodeficiency syndrome 29.5 HCP5 HLA-B IFNA2 IFNG IL10 IL2
33 fixed drug eruption 29.5 IFNG IL2
34 poliomyelitis 29.4 FCGR3A IFNG IL10
35 aphthous stomatitis 29.4 HLA-A HLA-B IL10 IL2
36 burning mouth syndrome 29.4 IL2 TRPV1
37 leprosy 3 29.4 IFNG IL10 IL2
38 cytomegalovirus retinitis 29.4 HLA-A HLA-B IFNG
39 aplastic anemia 29.1 HLA-A HLA-B IFNG IL2
40 malaria 28.5 GYPC HLA-A HLA-B IFNG IL10 IL2
41 geniculate herpes zoster 12.9
42 herpes zoster ophthalmicus 12.7
43 myoclonus and ataxia 12.2
44 congenital varicella syndrome 12.0
45 immunodeficiency 50 11.1
46 salivary gland disease 11.0
47 cytomegalic inclusion disease 11.0
48 aids - neurological complications 11.0
49 neurological consequences of cytomegalovirus infection 11.0
50 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster

Symptoms & Phenotypes for Herpes Zoster

Symptoms:

12
  • fever
  • paresthesia
  • headache
  • itching
  • malaise
  • rash which is followed by blisters
  • burning pain

UMLS symptoms related to Herpes Zoster:


seizures, tremor, fever, angina pectoris, pruritus, back pain, pain, headache, syncope, chronic pain, sciatica, exanthema, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Herpes Zoster

PubMedHealth treatment related to Herpes Zoster: 63

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin). Prescription painkillers are sometimes used to relieve more severe pain.Thorough skin care is recommended if you have shingles. Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters. Most of them contain tanins, zinc, menthol or polidocanol. If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work.Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system, if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 443)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
2
Acyclovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59277-89-3 2022
3
Ethanol Approved Phase 4 64-17-5 702
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
9
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
10
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
11
Capsaicin Approved Phase 4,Phase 3,Phase 2 404-86-4 1548943
12
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
13
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
14
Budesonide Approved Phase 4,Phase 2 51333-22-3 63006 5281004
15
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
16
Methotrexate Approved Phase 4,Phase 3,Phase 2 59-05-2, 1959-05-2 126941
17
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
18
Tofacitinib Approved, Investigational Phase 4,Phase 2 477600-75-2
19
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
20
Natalizumab Approved, Investigational Phase 4 189261-10-7
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Infliximab Approved Phase 4,Phase 3 170277-31-3
24
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
25
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
26
Certolizumab pegol Approved Phase 4 428863-50-7
27
Azathioprine Approved Phase 4 446-86-6 2265
28
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
32
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
33
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
34
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
35 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
41 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
43 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Ketorolac Tromethamine Phase 4
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 554)
# Name Status NCT ID Phase Drugs
1 The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
2 Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
3 The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
4 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
5 Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine Unknown status NCT02514018 Phase 4
6 Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Unknown status NCT01982409 Phase 4
7 Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Unknown status NCT00940940 Phase 4
8 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
9 "Equistasi" and Gait in Hemiparesis Unknown status NCT02714478 Phase 4
10 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
11 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
12 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
13 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Completed NCT01911065 Phase 4
14 Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
15 Safety of a Second Dose of Biken's Varicella Vaccine Completed NCT00830648 Phase 4
16 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
17 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) Completed NCT01556451 Phase 4
18 Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Completed NCT00885586 Phase 4 gabapentine
19 Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
20 Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) Completed NCT00681031 Phase 4
21 Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT01817270 Phase 4
22 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
23 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
24 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
25 Varicella Vaccination With Pulmicort Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
26 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Completed NCT00550745 Phase 4
27 Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
28 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
29 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
30 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
31 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Completed NCT01693380 Phase 4
32 Palatability Testing of a New Paediatric Formulation of Valacyclovir Completed NCT01682109 Phase 4 Valacyclovir
33 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
34 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
35 An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
36 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
37 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
38 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
39 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
40 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed NCT00048165 Phase 4 Daclizumab;Methylprednisolone;Mycophenolate mofetil;Placebo;cyclosporine
41 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
42 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
43 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
44 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Recruiting NCT03493776 Phase 4
45 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
46 Immune Response to Shingles Vaccination Recruiting NCT02624375 Phase 4 Zoster Vaccine Live
47 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
48 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
49 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia Recruiting NCT03809702 Phase 4 Pregabalin;Placebo
50 Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Recruiting NCT03620526 Phase 4 Iloprost;Placebo

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: herpes zoster

Genetic Tests for Herpes Zoster

Anatomical Context for Herpes Zoster

MalaCards organs/tissues related to Herpes Zoster:

41
Skin, Eye, T Cells, Testes, Brain, Kidney, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

19
Nerve Fiber

Publications for Herpes Zoster

Articles related to Herpes Zoster:

(show top 50) (show all 2423)
# Title Authors Year
1
Current Practice Patterns and Opinions on the Management of Recent-Onset or Chronic Herpes Zoster Ophthalmicus of Zoster Eye Disease Study Investigators. ( 30157049 )
2019
2
Ultrasound guided bi-level erector spinae plane block for pain management in Herpes Zoster. ( 30170249 )
2019
3
Case Series: Herpes Zoster Ophthalmicus with Acute Orbital Inflammation. ( 29554007 )
2018
4
Herpes zoster at the vaccination site in immunized healthy children. ( 29405375 )
2018
5
Herpes zoster subunit vaccine for the prevention of herpes zoster. ( 29880523 )
2018
6
Treatment of herpes zoster ophthalmicus: a systematic review and Canadian cost-comparison. ( 29631821 )
2018
7
Statins increase the risk of herpes zoster: A propensity score-matched analysis. ( 29902266 )
2018
8
Associations of Perceived Mental Stress, Sense of Purpose in Life, and Negative Life Events With the Risk of Incident Herpes Zoster and Postherpetic Neuralgia: The SHEZ Study. ( 29036443 )
2018
9
Quantifying the incidence and burden of herpes zoster in New Zealand general practice: a retrospective cohort study using a natural language processing software inference algorithm. ( 29858420 )
2018
10
Epidemiology and long-term disease burden of herpes zoster and postherpetic neuralgia in Taiwan: a population-based, propensity score-matched cohort study. ( 29554872 )
2018
11
Herpes zoster multiplex: Report on one case. ( 29884454 )
2018
12
A case of cutaneous metastasis mimicking herpes zoster rash. ( 29942781 )
2018
13
Herpes zoster ophthalmicus: acute keratitis. ( 29794881 )
2018
14
Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer. ( 28786220 )
2018
15
Usefulness of Inflammatory Markers for the Prediction of Postherpetic Neuralgia in Patients with Acute Herpes Zoster. ( 29606812 )
2018
16
Herpes zoster complicated by unilateral pleural effusion. ( 29976542 )
2018
17
Herpes Zoster: Hand Dominance the Missing Link to Unilaterality? ( 29854652 )
2018
18
Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. ( 29366704 )
2018
19
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. ( 29390929 )
2018
20
Management of chronic complications associated with herpes zoster ophthalmicus. ( 29708930 )
2018
21
Using natural language processing for identification of herpes zoster ophthalmicus cases to support population-based study. ( 29920898 )
2018
22
Herpes zoster ophthalmicus evolving into headache characterised as hemicrania continua. ( 29574434 )
2018
23
Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. ( 29958739 )
2018
24
Herpes zoster chronification to postherpetic neuralgia induces brain activity and grey matter volume change. ( 29423004 )
2018
25
In Reply-Human Immunodeficiency Virus and Herpes Zoster: Could the Link Be Ignored? ( 29866284 )
2018
26
Human Immunodeficiency Virus and Herpes Zoster: Could the Link Be Ignored? ( 29866286 )
2018
27
The Skin and the Eye - Herpes Zoster Ophthalmicus in a Healthy 18-month-old Toddler. ( 29668453 )
2018
28
Discoid lupus erythematosus following herpes zoster. ( 29894527 )
2018
29
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. ( 29850873 )
2018
30
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. ( 29370152 )
2018
31
Effectiveness of continuous epidural analgesia on acute herpes zoster and postherpetic neuralgia: A retrospective study. ( 29384888 )
2018
32
Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. ( 29409017 )
2018
33
An unusual eruption following herpes zoster infection. ( 29876966 )
2018
34
Heightened risk of ischemic stroke after recent herpes zoster ophthalmicus. ( 29717486 )
2018
35
Herpes Zoster Ophthalmicus With Orbital Findings Preceding Skin Rash. ( 29634608 )
2018
36
Wolf's isotopic nonresponse in healed herpes zoster in erythroderma. ( 29393080 )
2018
37
Unusual case of hemidiaphragmatic paralysis secondary to cervical herpes zoster. ( 29367364 )
2018
38
Is High Altitude a Risk Factor in Development of Herpes Zoster? ( 29957066 )
2018
39
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
40
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. ( 29880565 )
2018
41
Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis. ( 29419465 )
2018
42
Herpes zoster ophthalmicus. ( 29807938 )
2018
43
Herpes zoster ophthalmicus: Pre-eruption phase sine herpete. ( 29552667 )
2018
44
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine. ( 29868745 )
2018
45
Age-dependent trigeminal and female-specific lumbosacral increase in herpes zoster distribution in the elderly. ( 29395575 )
2018
46
Orbital Apex Syndrome Secondary to Herpes Zoster Ophthalmicus. ( 29576898 )
2018
47
Herpes zoster with cutaneous dissemination: a rare presentation of an uncommon pathology in children. ( 29895579 )
2018
48
Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged a8Y50 years: A prospective study. ( 29428228 )
2018
49
High resolution vessel wall MRI and vasculopathy related to herpes zoster ophthalmicus. ( 29754069 )
2018
50
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018

Variations for Herpes Zoster

Expression for Herpes Zoster

Search GEO for disease gene expression data for Herpes Zoster.

Pathways for Herpes Zoster

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 HLA-A HLA-B IFNA2 IFNG IL10 IL2
2
Show member pathways
12.62 HLA-A HLA-B IFNA2 IFNG IL2
3
Show member pathways
12.62 HLA-A HLA-B IFNA2 IFNG IL10 IL2
4
Show member pathways
12.37 HLA-A HLA-B IFNA2 IFNG
5
Show member pathways
12.23 IFNA2 IFNG IL10 IL2
6 12.06 FCGR3A IFNA2 IFNG IL10
7 11.97 FCGR3A HLA-A HLA-B
8 11.91 FCGR3A HLA-A HLA-B
9
Show member pathways
11.89 IFNG IL10 IL2
10
Show member pathways
11.81 HLA-A IFNG IL2
11 11.73 IFNA2 IFNG IL10 IL2
12 11.7 IFNA2 IFNG IL10 IL2
13 11.64 IFNG IL10 IL2
14
Show member pathways
11.64 HLA-A HLA-B IFNA2 IFNG IL10 IL2
15
Show member pathways
11.58 FCGR3A HLA-A HLA-B IFNA2 IFNG IL2
16
Show member pathways
11.51 HLA-A IFNG IL2
17 11.43 IFNA2 IFNG IL10 IL2
18 11.39 GYPC IFNG IL10
19 11.33 IFNG IL10 IL2
20 11.31 FCGR3A IFNG IL10 IL2
21 11.22 HLA-B IFNA2 IFNG
22 11.07 IFNG IL2
23 11.07 IFNG IL10 IL2
24 11.02 HLA-A HLA-B
25 10.91 IFNG IL10 IL2

GO Terms for Herpes Zoster

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-A HLA-B
2 MHC class I protein complex GO:0042612 8.62 HLA-A HLA-B

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.81 IFNA2 IFNG IL10 IL2
2 interferon-gamma-mediated signaling pathway GO:0060333 9.58 HLA-A HLA-B IFNG
3 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.54 HLA-A HLA-B
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IFNG IL2
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.52 HLA-A HLA-B
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.49 HLA-A HLA-B
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.48 IFNA2 IFNG
8 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG IL2
9 regulation of immune response GO:0050776 9.46 COL17A1 FCGR3A HLA-A HLA-B
10 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.43 HLA-A HLA-B
11 type I interferon signaling pathway GO:0060337 9.43 HLA-A HLA-B IFNA2
12 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.32 HLA-A HLA-B
13 immune response GO:0006955 9.1 FCGR3A HLA-A HLA-B IFNG IL10 IL2
14 protection from natural killer cell mediated cytotoxicity GO:0042270 8.96 HLA-A HLA-B

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNA2 IFNG IL10 IL2

Sources for Herpes Zoster

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....